Period
recent search
Showing: 1 – 05 of 171 Regulated Information
22 January 2024
22 January 2024
Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
PARIS, FRANCE, 22 January 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today new data to be presented for Cabometyx® (cabozantinib) in combination with immunotherapy across indications at the upcoming American Society of Clinical Oncology Genitourinary Symposium (ASCO GU) taking…
08 January 2024
08 January 2024
Ipsen – Half year statement – 2023 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
05 January 2024
05 January 2024
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
07 December 2023
07 December 2023
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
07 December 2023
07 December 2023
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
PARIS, FRANCE, 07 December 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily…